NASDAQ:AUPH
Aurinia Pharmaceuticals Inc Stock News
$5.10
-0.0700 (-1.35%)
At Close: May 03, 2024
Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?
01:12pm, Friday, 21'st Oct 2022 Zacks Investment Research
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?
10:32am, Friday, 21'st Oct 2022
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval
04:04pm, Tuesday, 20'th Sep 2022 Zacks Investment Research
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval
01:33pm, Tuesday, 20'th Sep 2022
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model
11:53am, Monday, 15'th Aug 2022
LUPKYNIS revenues and company net losses are tracking better than my valuation model predicts -- and new European revenues are on the horizon. However, expenses continue to rise, which is contrary to
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
11:30am, Tuesday, 09'th Aug 2022 Benzinga
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.
Needham lowered the price target
Why Aurinia Pharmaceuticals Stock Briefly Spiked Today
03:58pm, Thursday, 04'th Aug 2022 The Motley Fool
Investors embraced the biotech's second-quarter results.
Aurinia Pharmaceuticals Inc's (AUPH) CEO Peter Greenleaf on Q2 2022 Results - Earnings Call Transcript
12:02pm, Thursday, 04'th Aug 2022
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants DeDe Sheel – Vice President-Investor Relations Peter Greenleaf – Preside
Why Aurinia Pharmaceuticals Stock Briefly Spiked Today
11:58am, Thursday, 04'th Aug 2022
Investors embraced the biotech's second-quarter results.
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
11:35am, Thursday, 04'th Aug 2022 Zacks Investment Research
Aurinia (AUPH) delivered earnings and revenue surprises of -13.64% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
09:02am, Thursday, 04'th Aug 2022
Aurinia (AUPH) delivered earnings and revenue surprises of -13.64% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Aurinia Pharmaceuticals Stock Is Sliding Today
04:22pm, Wednesday, 27'th Jul 2022 The Motley Fool
An analyst downgraded the stock.
Why Aurinia Pharmaceuticals Stock Is Sliding Today
12:22pm, Wednesday, 27'th Jul 2022
An analyst downgraded the stock.
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
09:29am, Wednesday, 27'th Jul 2022 Benzinga
Gainers
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Pag
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
04:07pm, Monday, 25'th Jul 2022
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operat
